Natera

Traded on the St. Petersburg Stock Exchange
Natera is an American clinical genetic testing company that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. It was founded in 2003 and is headquartered in San Carlos, California.
Natera stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Natera balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Natera cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Natera multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Natera profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Natera assets
Natera cash flows

Natera dividend policy

The company doesn't provide dividends

Natera shares

TickerNameTypeNominal valueISINPrice
NTRA:USNateraCommon share-US6323071042$85.28
Natera news
06.05.2022
Natera's GAAP loss for 3 months of 2022 was $138.595 million, up 2.2 times from $63.853 million in the previous year. Revenue increased by 27.5% to $194.133 million compared to $152.316 million a year earlier.
Source: {source} pictogram investor.natera.com
Pictogram next
25.02.2022
Natera's GAAP loss for 2021 was $471.716 million, up 2.1 times from $229.743 million in the previous year. Revenue increased 60% to $625.486 million compared to $391.005 million a year earlier.
Source: {source} pictogram investor.natera.com
Pictogram next
05.11.2021
Natera reported a GAAP loss of $331.152 million for 9M 2021, up 2.2 times from $153.331 million in the previous year. Revenue increased by 62.4% to $452.458 million compared to $278.627 million a year earlier.
Source: {source} pictogram natera.gcs-web.com
Pictogram next
All Natera news
General information
Company nameNatera
Tags#cancer treatment, #genome
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address201 Industrial Road Suite 410 San Carlos, CA 94070 United States
Mailing address201 Industrial Road Suite 410 San Carlos, CA 94070 United States
Websitenatera.gcs-web.com